PTC Therapeutics Inc (PTCT) - Total Liabilities
Based on the latest financial reports, PTC Therapeutics Inc (PTCT) has total liabilities worth $3.05 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PTC Therapeutics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
PTC Therapeutics Inc - Total Liabilities Trend (2004–2025)
This chart illustrates how PTC Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is PTC Therapeutics Inc's balance sheet.
PTC Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of PTC Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Swatch Group AG Class N
SW:UHRN
|
Switzerland | CHF1.98 Billion |
|
Balchem Corporation
NASDAQ:BCPC
|
USA | $408.63 Million |
|
United Plantations Bhd
KLSE:2089
|
Malaysia | RM548.41 Million |
|
Gland Pharma Limited
NSE:GLAND
|
India | Rs21.53 Billion |
|
Almonty Industries Inc
AU:AII
|
Australia | AU$231.92 Million |
|
Flagstar Financial, Inc.
NYSE:FLG
|
USA | $79.01 Billion |
|
TEMENOS AG UNSP.ADR/1
F:TE8A
|
Germany | €1.83 Billion |
|
TDG Holding Co Ltd
SHG:600330
|
China | CN¥3.54 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down PTC Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See PTC Therapeutics Inc (PTCT) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -16.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PTC Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PTC Therapeutics Inc (2004–2025)
The table below shows the annual total liabilities of PTC Therapeutics Inc from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.12 Billion | +11.18% |
| 2024-12-31 | $2.80 Billion | +3.27% |
| 2023-12-31 | $2.71 Billion | +32.23% |
| 2022-12-31 | $2.05 Billion | +5.99% |
| 2021-12-31 | $1.94 Billion | +12.18% |
| 2020-12-31 | $1.73 Billion | +67.69% |
| 2019-12-31 | $1.03 Billion | +33.96% |
| 2018-12-31 | $768.50 Million | +226.72% |
| 2017-12-31 | $235.22 Million | +57.06% |
| 2016-12-31 | $149.76 Million | +115.26% |
| 2015-12-31 | $69.57 Million | +100.20% |
| 2014-12-31 | $34.75 Million | +126.24% |
| 2013-12-31 | $15.36 Million | -52.40% |
| 2012-12-31 | $32.27 Million | -88.59% |
| 2011-12-31 | $282.75 Million | +4973.62% |
| 2005-12-31 | $5.57 Million | +27.97% |
| 2004-12-31 | $4.36 Million | -- |
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervo… Read more